;PMID: 7947263
;source_file_1232.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..36] = [t:0..36]
;1)sentence:[e:41..174] = [t:41..174]
;2)section:[e:178..230] = [t:178..230]
;3)section:[e:234..301] = [t:234..301]
;4)sentence:[e:305..437] = [t:305..437]
;5)sentence:[e:438..727] = [t:438..727]
;6)sentence:[e:728..931] = [t:728..931]
;7)sentence:[e:932..1039] = [t:932..1039]
;8)section:[e:1043..1087] = [t:1043..1087]

;section 0 Span:0..36
;Br J Haematol  1994 Jun;87(2):235-42
(SEC
  (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..13] Haematol) (CD:[15..19] 1994)
        (CC:[20..27] Jun;87-LRB-) (CD:[27..28] 2) (-RRB-:[28..29] -RRB-)
        (CD:[29..33] :235) (::[33..34] -) (CD:[34..36] 42)))

;sentence 1 Span:41..174
;Establishment and characterization of a novel myeloid cell line from the bone
; marrow of a patient with the myelodysplastic syndrome.
;[87..104]:malignancy:"myeloid cell line"
;[149..173]:malignancy:"myelodysplastic syndrome"
(SENT
  (NP-HLN
    (NP (NN:[41..54] Establishment) (CC:[55..58] and)
        (NN:[59..75] characterization))
    (PP (IN:[76..78] of)
      (NP
        (NP (DT:[79..80] a) (JJ:[81..86] novel)
           (JJ:[87..94] myeloid) (NN:[95..99] cell) (NN:[100..104] line))
        (PP (IN:[105..109] from)
          (NP
            (NP (DT:[110..113] the) (NN:[114..118] bone) (NN:[120..126] marrow))
            (PP (IN:[127..129] of)
              (NP
                (NP (DT:[130..131] a) (NN:[132..139] patient))
                (PP (IN:[140..144] with)
                  (NP (DT:[145..148] the)
                     (JJ:[149..164] myelodysplastic) (NN:[165..173] syndrome)))))))))
    (.:[173..174] .)))

;section 2 Span:178..230
;Tohyama K, Tsutani H, Ueda T, Nakamura T, Yoshida Y.
(SEC
  (FRAG (NNP:[178..185] Tohyama) (NNP:[186..187] K) (,:[187..188] ,)
        (NNP:[189..196] Tsutani) (NNP:[197..198] H) (,:[198..199] ,)
        (NNP:[200..204] Ueda) (NNP:[205..206] T) (,:[206..207] ,)
        (NNP:[208..216] Nakamura) (NNP:[217..218] T) (,:[218..219] ,)
        (NNP:[220..227] Yoshida) (NNP:[228..230] Y.)))

;section 3 Span:234..301
;First Department of Internal Medicine, Fukui Medical School, Japan.
(SEC
  (FRAG (NNP:[234..239] First) (NNP:[240..250] Department) (IN:[251..253] of)
        (NNP:[254..262] Internal) (NNP:[263..271] Medicine) (,:[271..272] ,)
        (NNP:[273..278] Fukui) (NNP:[279..286] Medical) (NNP:[287..293] School)
        (,:[293..294] ,) (NNP:[295..300] Japan) (.:[300..301] .)))

;sentence 4 Span:305..437
;A novel long-term cultured myeloid cell line was established from the bone 
;marrow of a patient with myelodysplastic syndrome (MDS).
;[332..349]:malignancy:"myeloid cell line"
;[406..430]:malignancy:"myelodysplastic syndrome"
;[432..435]:malignancy:"MDS"
(SENT
  (S
    (NP-SBJ-1 (DT:[305..306] A) (JJ:[307..312] novel)
      (NML (JJ:[313..317] long) (HYPH:[317..318] -) (NN:[318..322] term))
      (VBN:[323..331] cultured)
       (JJ:[332..339] myeloid) (NN:[340..344] cell) (NN:[345..349] line))
    (VP (VBD:[350..353] was)
      (VP (VBN:[354..365] established)
        (NP-1 (-NONE-:[365..365] *))
        (PP (IN:[366..370] from)
          (NP
            (NP (DT:[371..374] the) (NN:[375..379] bone) (NN:[381..387] marrow))
            (PP (IN:[388..390] of)
              (NP
                (NP (DT:[391..392] a) (NN:[393..400] patient))
                (PP (IN:[401..405] with)
                  (NP
                    (NP (JJ:[406..421] myelodysplastic) (NN:[422..430] syndrome))
                    (NP (-LRB-:[431..432] -LRB-) (NN:[432..435] MDS)
                        (-RRB-:[435..436] -RRB-))))))))))
    (.:[436..437] .)))

;sentence 5 Span:438..727
;This cell line,  designated MDS92, proliferated in the presence of
;interleukin-3 or  granulocyte-macrophage colony-stimulating factor and
;transiently in the presence  of Steel factor, with a tendency for gradual
;maturation, and formed myeloid  colonies in the semi-solid culture
;condition.
;[443..452]:malignancy:"cell line"
;[466..471]:malignancy:"MDS92"
;[505..518]:gene-protein:"interleukin-3"
;[523..571]:gene-protein:"granulocyte-macrophage colony-stimulating factor"
;[608..620]:gene-protein:"Steel factor"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[438..442] This)
         (NN:[443..447] cell) (NN:[448..452] line))
      (,:[452..453] ,)
      (VP (VBN:[455..465] designated)
        (S
          (NP-SBJ (-NONE-:[465..465] *))
          (NP-PRD (NN:[466..471] MDS92)))))
    (,:[471..472] ,)
    (VP
      (VP
        (VP (VBD:[473..485] proliferated)
          (PP=1 (IN:[486..488] in)
            (NP
              (NP (DT:[489..492] the) (NN:[493..501] presence))
              (PP (IN:[502..504] of)
                (NP
                  (NP (NN:[505..518] interleukin-3))
                  (CC:[519..521] or)
                  (NP
                    (NML (NN:[523..534] granulocyte) (HYPH:[534..535] -)
                         (NN:[535..545] macrophage))
                    (NML (NN:[546..552] colony) (HYPH:[552..553] -)
                         (VBG:[553..564] stimulating))
                    (NN:[565..571] factor)))))))
        (CC:[572..575] and)
        (VP
          (ADVP (RB:[576..587] transiently))
          (PP=1 (IN:[588..590] in)
            (NP
              (NP (DT:[591..594] the) (NN:[595..603] presence))
              (PP (IN:[605..607] of)
                (NP (NNP:[608..613] Steel) (NN:[614..620] factor)))))
          (,:[620..621] ,)
          (PP (IN:[622..626] with)
            (NP
              (NP (DT:[627..628] a) (NN:[629..637] tendency))
              (PP (IN:[638..641] for)
                (NP (JJ:[642..649] gradual) (NN:[650..660] maturation)))))))
      (,:[660..661] ,) (CC:[662..665] and)
      (VP (VBD:[666..672] formed)
        (NP (JJ:[673..680] myeloid) (NNS:[682..690] colonies))
        (PP (IN:[691..693] in)
          (NP (DT:[694..697] the)
            (NML
              (ADJP (AFX:[698..702] semi) (HYPH:[702..703] -)
                    (JJ:[703..708] solid))
              (NN:[709..716] culture))
            (NN:[717..726] condition)))))
    (.:[726..727] .)))

;sentence 6 Span:728..931
;In addition, the MDS92 cell line  represented rather complicated karyotypic
;abnormalities including the deletion  of fifth and seventh chromosomes and a
;point mutation at codon 12 of the N-ras  oncogene.
;[745..760]:malignancy:"MDS92 cell line"
;[832..840]:variation-type:"deletion"
;[845..850]...[855..862]...[863..874]:variation-location:"fifth"..."seventh"..
;."chromosomes"
;[881..895]:variation-type:"point mutation"
;[899..907]:variation-location:"codon 12"
;[915..920]:gene-rna:"N-ras"
(SENT
  (S
    (PP (IN:[728..730] In)
      (NP (NN:[731..739] addition)))
    (,:[739..740] ,)
    (NP-SBJ (DT:[741..744] the)
       (NN:[745..750] MDS92) (NN:[751..755] cell) (NN:[756..760] line))
    (VP (VBD:[762..773] represented)
      (NP
        (NP (RB:[774..780] rather) (JJ:[781..792] complicated)
            (JJ:[793..803] karyotypic) (NNS:[804..817] abnormalities))
        (PP (VBG:[818..827] including)
          (NP
            (NP
              (NP (DT:[828..831] the) (NN:[832..840] deletion))
              (PP (IN:[842..844] of)
                (NP
                  (NP (JJ:[845..850] fifth)
                    (NML-1 (-NONE-:[850..850] *P*)))
                  (CC:[851..854] and)
                  (NP (JJ:[855..862] seventh)
                    (NML-1 (NNS:[863..874] chromosomes))))))
            (CC:[875..878] and)
            (NP
              (NP (DT:[879..880] a)
                 (NN:[881..886] point) (NN:[887..895] mutation))
              (PP-LOC (IN:[896..898] at)
                (NP
                  (NP (NN:[899..904] codon) (CD:[905..907] 12))
                  (PP (IN:[908..910] of)
                    (NP (DT:[911..914] the) (NN:[915..920] N-ras)
                        (NN:[922..930] oncogene))))))))))
    (.:[930..931] .)))

;sentence 7 Span:932..1039
;These characteristics of the MDS92 cell line are exclusively  compatible with
;the property of preleukaemia.
;[961..976]:malignancy:"MDS92 cell line"
;[1026..1038]:malignancy:"preleukaemia"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[932..937] These) (NNS:[938..953] characteristics))
      (PP (IN:[954..956] of)
        (NP (DT:[957..960] the)
           (NN:[961..966] MDS92) (NN:[967..971] cell) (NN:[972..976] line))))
    (VP (VBP:[977..980] are)
      (ADVP (RB:[981..992] exclusively))
      (ADJP-PRD (JJ:[994..1004] compatible)
        (PP (IN:[1005..1009] with)
          (NP
            (NP (DT:[1010..1013] the) (NN:[1014..1022] property))
            (PP (IN:[1023..1025] of)
              (NP (NN:[1026..1038] preleukaemia)))))))
    (.:[1038..1039] .)))

;section 8 Span:1043..1087
;PMID: 7947263 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1043..1047] PMID) (::[1047..1048] :) (CD:[1049..1056] 7947263)
        (NN:[1057..1058] -LSB-) (NNP:[1058..1064] PubMed) (::[1065..1066] -)
        (NN:[1067..1074] indexed) (IN:[1075..1078] for)
        (NNP:[1079..1087] MEDLINE-RSB-)))
